Cargando…
Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model
BACKGROUND: Atrial fibrillation (AF) is the most common form of heart arrhythmia and a leading cause of stroke and systemic embolism. Chronic anticoagulation is recommended for preventing those complications. Our study aimed to compare the cost/utility (CU) of three main anticoagulation options: 1)...
Autores principales: | Nshimyumukiza, Léon, Duplantie, Julie, Gagnon, Mathieu, Douville, Xavier, Fournier, Diane, Lindsay, Carmen, Parent, Marc, Milot, Alain, Giguère, Yves, Gagné, Christian, Rousseau, François, Reinharz, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765702/ https://www.ncbi.nlm.nih.gov/pubmed/23866305 http://dx.doi.org/10.1186/1477-9560-11-14 |
Ejemplares similares
-
An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures
por: Nshimyumukiza, Léon, et al.
Publicado: (2013) -
Cost‐effectiveness analysis of antiviral treatment in the management of seasonal influenza A: point‐of‐care rapid test versus clinical judgment
por: Nshimyumukiza, Léon, et al.
Publicado: (2016) -
Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study
por: Wang, Shirley V, et al.
Publicado: (2016) -
Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores)
por: Branco, Claudia C, et al.
Publicado: (2009) -
Warfarin-related nephropathy: possible role for the warfarin pharmacogenetic profile
por: Di Maso, Vittorio, et al.
Publicado: (2014)